Openbookopenbook
Equity
BVS
+0.0 · +0.00%
USD · NASDAQ

Bioventus Inc(BVS) Stock Analysis | Healthcare

USD --+0.00%
Reward64Moderate
Risk38Moderate
75%Data
Quality Compounder
Market Cap:982.23M
ⓘ
Reward Rating
64
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
38
Moderate
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BVS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for BVS, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $17.60.

What is Bioventus Inc?

, a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.

BVS · Verdict

Solid reward · moderate risk

BVS scores well on profitability and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

BVS · Verdict

What’s working & what to watch

Strengths 5

  • Profitability74/100

    4% net margin · 26% ROE

  • Cash flow74/100

    13% free-cash-flow margin

  • Growth68/100

    Revenue +3.5% CAGR

  • Valuation67/100

    P/E 18.3× · PEG 1.83

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Bioventus Inc?

, a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 982.23M, and a P/E ratio of 18.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

QDELSmall Cap / 981M market cap
Quidel Corporation
Compare
LFTSFSmall Cap / 1B market cap
LifeTech Scientific Corporation
Compare
CBLLSmall Cap / 929M market cap
CeriBell, Inc
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap982.23M
P/E Ratio18.4359
Dividend YieldN/A
Beta0.653
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
112,000 shares
$105k
0
6-9months
110,000 shares
$76k
0
9-12months
117,701 shares
$131k
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.